Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in CNS.” Supurnus’ offer beats Biogen’s unsolicited bid of about $7.22 per share, which arrived with a thud in late January.
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in CNS.” Supurnus’ offer beats Biogen’s unsolicited bid of about $7.22 per share, which arrived with a thud in late January.